J&J To Pay $400M Over Criminal Charge In Risperdal Case

Law360, Philadelphia (November 07, 2013, 9:01 PM ET) -- A Pennsylvania federal judge on Thursday approved a $400 million criminal penalty against Johnson & Johnson unit Janssen Pharmaceuticals Inc., part of a larger $2.2 billion settlement announced Monday, after the company formally admitted to improperly encouraging doctors to use Risperdal to treat dementia.

U.S. District Judge Timothy Savage approved the sentence for one criminal misdemeanor charge of introducing a misbranded drug into interstate commerce, noting that the company's conduct had far greater consequences than those acknowledged in the plea.

“The company compromised the integrity of...
To view the full article, take a free trial now.
Try Law360 for free for seven days
Already a subscriber? Click here to login

Already have access?

  1. Forgot your password?
  2. Sign In

Get instant access to the one-stop news source for business lawyers

Required